Not Yet RecruitingNot Applicable

Risk-adapted Therapeutic Strategy in +1q NDMM

China200 participantsStarted 2025-09-15

Plain-language summary

This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) status as the primary endpoint.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>=18, or \>=65 and fit according to IMWG-FI. * Newly diagnosed NDMM by 2014 IMWG criteria. * Adequate organ function for systemic therapy. * Signed informed consent. Exclusion Criteria: * Active infections requiring systemic treatment. * Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias. * History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years. * Current malignancies requiring therapy. * Refusal to participate.